Recent Updates
Recently added Catalysts
VKTX Neutral Sentiment

Results From the 13-Week VENTURE Phase 2a Study of the GLP-1/GIP Co-Agonist VK2735 in Obese Patients

Friday, November 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the 13-week VENTURE Phase 2a study of VK2735, a GLP-1/GIP co-agonist, aimed at treating obesity in patients. The study's results are yet to be detailed, indicating a focus on the drug's potential efficacy and safety. Further insights into the study's outcomes may be anticipated in future communications.
Price reaction · baseline $72.54 (2024-10-31 close) · hit pre-market · 2 other VKTX headline(s) in the window, move may be shared
day 0 close
+0.5%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts
ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare VK2735 obesity Phase 2a clinical trial
Last updated: Nov 1, 2024

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →